Yep, the patent on this is a slam dunk I reckon.
The bigger question is why Veyonda has not been included in any of the large COVID trials yet. With such promising phase I data, it is strange that the company has not pushed harder for this. The whole COVID trial landscape is painfully political, but I'm beginning to think that there might be something else, given NOX are not interested in funding a NOXCOVID-2 themselves. Perhaps the immune suppressing aspects of the STING inhibition is TOO high? Perhaps they are just too busy and want to prioritise elsewhere? But clearly they are still pursuing the patent and have even paid for TrackOne prioritisation so we can't rule out surprise news at any time.
- Forums
- ASX - By Stock
- NOX
- HIMR
HIMR, page-2
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NOX (ASX) to my watchlist
|
|||||
Last
11.0¢ |
Change
0.005(4.76%) |
Mkt cap ! $37.99M |
Open | High | Low | Value | Volume |
12.5¢ | 14.0¢ | 11.0¢ | $458.2K | 3.617M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 550454 | 11.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
11.5¢ | 233032 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 550454 | 0.110 |
10 | 797329 | 0.105 |
13 | 736405 | 0.100 |
1 | 25357 | 0.098 |
3 | 21249 | 0.096 |
Price($) | Vol. | No. |
---|---|---|
0.115 | 233032 | 7 |
0.120 | 30000 | 2 |
0.125 | 301692 | 2 |
0.130 | 109000 | 2 |
0.135 | 441881 | 6 |
Last trade - 11.33am 03/09/2024 (20 minute delay) ? |
Featured News
NOX (ASX) Chart |